Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 9/2013

01-06-2013 | Adis Drug Evaluation

Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias

Author: Greg L. Plosker

Published in: Drugs | Issue 9/2013

Login to get access

Abstract

Landiolol (Onoact®) is an intravenously administered, ultra short-acting β1-blocker with an elimination half-life of 3–4 min and ≈8-fold greater cardioselectivity than esmolol in vitro. It is approved in Japan for the treatment of intraoperative and postoperative tachyarrhythmias, but in clinical practice is also used to prevent postoperative tachyarrhythmias, such as atrial fibrillation after coronary artery bypass grafting. Randomized controlled trials in patients undergoing open-heart surgery demonstrated that various dosages of landiolol (0.0005–0.04 mg/kg/min) [0.5–40 μg/kg/min] were more effective than diltiazem in converting postoperative atrial fibrillation to normal sinus rhythm during the first 8 h after surgery, and were more effective than placebo (or no landiolol) in preventing the development of atrial fibrillation during the first week after surgery (primary efficacy endpoints). In patients undergoing surgical procedures, landiolol 0.125 mg/kg/min for 1 min followed by 0.04 mg/kg/min for 10 min was superior to placebo in improving intraoperative tachycardia in randomized double-blind trials. The beneficial effects of landiolol in attenuating adverse haemodynamic or other changes that can occur during surgery or invasive procedures (e.g. percutaneous coronary intervention) have been demonstrated in a large number of randomized controlled trials. For example, several studies showed that landiolol attenuated the increase in heart rate associated with tracheal intubation, without adversely affecting blood pressure or other haemodynamic parameters. Landiolol was generally well tolerated in clinical trials, with a relatively low risk of hypotension and bradycardia, although routine monitoring of cardiac function during landiolol administration is important. In general, adverse events such as reduced blood pressure resolve quickly after discontinuation of landiolol. Thus, as an ultra short-acting β1-blocker with a rapid onset of action and readily titratable and rapidly reversible effects, landiolol represents an important agent for the management of intraoperative and postoperative tachyarrhythmias.
Literature
1.
Cardinale D, Martinoni A, Cipolla CM, et al. Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. Ann Thorac Surg. 1999;68(5):1827–31.CrossRefPubMed
2.
Roselli EE, Murthy SC, Rice TW, et al. Atrial fibrillation complicating lung cancer resection. J Thorac Cardiovasc Surg. 2005;130(2):438–44.CrossRefPubMed
3.
Creswell LL, Schuessler RB, Rosenbloom M, et al. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56(3):539–49.CrossRefPubMed
4.
Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94(3):390–7.CrossRefPubMed
5.
Melduni RM, Koshino Y, Shen WK. Management of arrhythmias in the perioperative setting. Clin Geriatr Med. 2012;28(4):729–43.CrossRefPubMed
6.
Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg. 1997;226(4):501–11 (discussion 11–3).
7.
Vaporciyan AA, Correa AM, Rice DC, et al. Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg. 2004;127(3):779–86.CrossRefPubMed
8.
9.
Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull. 1992;40(6):1462–9.CrossRefPubMed
10.
Yamakage M, Iwasaki S, Jeong S-W, et al. Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009;38(1):48–55.CrossRefPubMed
11.
Motomura S, Hagihara A, Narumi Y, et al. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol. 1998;31(3):431–40.CrossRefPubMed
12.
Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol. 1999;34(1):70–7.CrossRefPubMed
13.
Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β-blocking agent in healthy volunteers (in Japanese). Rinsho Iyaku. 1997;13:4823–50.
14.
Mizuno J, Yoshiya I, Yokoyama T, et al. Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia. Eur J Clin Pharmacol. 2007;63(3):243–52.CrossRefPubMed
15.
Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22(4):361–6.CrossRefPubMed
16.
Shibata S, Okamoto Y, Endo S, et al. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118(2):255–65.CrossRefPubMed
17.
Frishman WH, Saunders E. β-adrenergic blockers. J Clin Hypertens. 2011;13(9):649–53.CrossRef
18.
Kimura-Kurosawa S, Kanaya N, Kamada N, et al. Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart. J Anesth. 2007;21(4):480–9.CrossRefPubMed
19.
Kurosawa S, Kanaya N, Niiyama Y, et al. Landiolol, esmolol and propranolol protect from ischemia/reperfusion injury in isolated guinea pig hearts. Can J Anaesth. 2003;50(5):489–94.CrossRefPubMed
20.
Zhao H, Sugawara T, Miura S, et al. Intrathecal landiolol inhibits nociception and spinal c-Fos expression in the mouse formalin test. Can J Anaesth. 2007;54(3):201–7.CrossRefPubMed
21.
Kurita T, Takata K, Morita K, et al. Lipophilic β-adrenoceptor antagonist propranolol increases the hypnotic and anti-nociceptive effects of isoflurane in a swine model. Br J Anaesth. 2008;100(6):841–5.CrossRefPubMed
22.
Tsunekawa K, Imawaka H, Yamamoto K, et al. Studies on the metabolic fate of ultra short acting β1-blocker ONO-1101 (3): metabolism and protein binding (in Japanese). Xenobio Metab Dispos. 1997;12:31–41.
23.
Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β1-blocking agent in healthy volunteers (in Japanese). J Clin Ther Med. 2000;16(10):1531–56.
24.
Honda N, Nakade S, Kasai H, et al. Population pharmacokinetics of landiolol hydrochloride in healthy subjects. Drug Metab Pharmacokinet. 2008;23(6):447–55.CrossRefPubMed
25.
Murakami M, Furuie H, Matsuguma K, et al. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting β1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet. 2005;20(5):337–44.CrossRefPubMed
26.
Matsumoto N, Aomori T, Kanamoto M, et al. Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. Biol Pharm Bull. 2012;35(10):1655–60.CrossRefPubMed
27.
Atarashi H, Kuruma A, Yashima M, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143–50.CrossRefPubMed
28.
Takahata T, Yasui-Furukori N, Sakamoto J, et al. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting β1-blocker. Drugs R D. 2005;6(6):385–94.CrossRefPubMed
29.
Inoue S, Abe R, Kawaguchi M, et al. Metoclopramide does not prolong duration of action of landiolol attenuating the hemodynamic response to induction of anesthesia and tracheal intubation. J Anesth. 2010;24(4):649–52.CrossRefPubMed
30.
Suzuki T, Aono M, Isaka T, et al. Effect of landiolol hydrochloride on suxamethonium-induced neuromuscular block. J Anesth. 2009;23(2):188–91.CrossRefPubMed
31.
Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141(6):1478–87.CrossRefPubMed
32.
Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144(5):1241–8.CrossRefPubMed
33.
Sakamoto A, Kitakaze M, Takamoto S, et al. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J. 2012;76(5):1097–101.CrossRefPubMed
34.
Fujii M, Bessho R, Ochi M, et al. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg (Torino). 2012;53(3):369–74.
35.
Osada H, Nakajima H, Masuyama S, et al. Landiolol hydrochloride: prevention of atrial fibrillation after open-heart surgery (abstract no. P606). Eur Heart J. 2012;33:65.
36.
37.
Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012;53(6):359–63.PubMed
38.
Ito N, Tashiro T, Morishige N, et al. Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction. Heart Surg Forum. 2012;15(4):E189–94.CrossRefPubMed
39.
Tanaka K. Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2010;63(3):175–9 (discussion 9–83).
40.
Fujiwara H, Sakurai M, Namai A, et al. Effect of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg. 2009;57(3):132–7.CrossRefPubMed
41.
Yoshida Y, Terajima K, Sato C, et al. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22(1):64–9.CrossRefPubMed
42.
To K, Iseki S, Setoguchi H. Landiolol hydrochloride improves the surgical Apgar score and outcome in off-pump coronary artery bypass surgery (abstract no. 700.00). Br J Anaesth. 2012;108:ii238.
43.
Wakamatsu H, Yokoyama H. Intraoperative infusion of landiolol hydrochloride, an ultra-short acting beta-1 adrenergic receptor blocker, prevents postoperative atrial fibrillation after off-pump coronary artery bypass surgery (abstract). Chest. 2011;140(4 Meeting Abstracts):508A.
44.
Uehara K, Ueyama K, Ito H, et al. Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone? (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2010;63(3):188–91.
45.
Ito S, Konishi T, Imazuru T, et al. Comparative study between landiolol and amiodarone for therapeutic efficacy after open heart surgery (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2011;64(13):1141–4.
46.
Nakanishi K, Takeda S, Kim C, et al. Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. J Cardiothorac Surg. 2013;8:19.CrossRefPubMed
47.
Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a phase III, double-blind study in comparison with placebo (in Japanese). Rinsyoiyaku (J Clin Ther Med). 1997;13:4949–78.
48.
Yoshiya I, Ogawa R, Yasuhiro S. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia in patients with hypertension or cardiac ischemia: double-blind study in comparison with placebo (in Japanese). Rinsyoiyaku (J Clin Ther Med). 2002;18(9):1049–76.
49.
Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of an ultra short acting beta-1-blocker landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a double-blind, dose finding study (late phase II study) (in Japanese). Rinsyoiyaku (J Clin Ther Med). 2000;16(10):1557–77.
50.
Tanaka N, Watanabe T, Mishima T, et al. Prevention of atrial fibrillation recurrence with low-dose landiolol administration after radiofrequency catheter ablation (abstract). J Cardiovasc Electrophysiol. 2011;22:S109.
51.
Nojiri T, Yamamoto K, Maeda H, et al. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Gen Thorac Cardiovasc Surg. 2011;59(12):799–805.CrossRefPubMed
52.
Wariishi S, Yamashita K, Nishimori H, et al. Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. Interact Cardiovasc Thorac Surg. 2009;9(5):811–3.CrossRefPubMed
53.
Nakano T, Shimizu K, Kawashima O, et al. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. J Clin Pharm Ther. 2012;37(4):431–5.CrossRefPubMed
54.
Uratsuji Y, Ijichi K, Irie J, et al. Effect of landiolol hydrochloride (ONO-1101) infusion on perioperative supraventricular tachyarrhythmia in several times (in Japanese). Rinsyoiyaku (J Clin Ther Med). 1997;13:5009–26.
55.
Ishigaki D, Arimoto T, Iwayama T, et al. Landiolol, an ultrashort-acting β-blocker, for prevention of atrial fibrillation after catheter ablation (abstract no. P2374). Eur Heart J. 2012;33:352.
56.
Koyanagi K, Seishima R, Tabuchi S, et al. Usefulness of short-acting β1 selective blocker (landiolol hydrochloride) for postoperative tachyarrhythmia after radical operation of esophageal cancer (abstract). Dis Esophagus. 2010;23:114A–5A.
57.
Okita T, Uji M, Shinjo T, et al. Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection (in Japanese). Jpn J Anesthesiol. 2008;57(8):953–8.
58.
Sugimoto R, Nakayama Y, Nawa Y. Administration of landiolol decreases the incidence of atrial fibrillation after lung lobectomy (abstract no. A1141). Annual Meeting of the American Society of Anesthesiologists, San Diego;2010.
59.
Taenaka N, Amaha K. Dose-dependent effect of landiolol, a new ultra-short-acting β1-blocker, on supraventricular tachyarrhythmias in postoperative patients. Clin Drug Investig. 2013; doi:10.​1007/​s40261-013-0093x.
60.
Kawaguchi M, Utada K, Yoshitani K, et al. Effects of a short-acting β1-receptor antagonist landiolol on hemodynamics and tissue injury markers in patients with subarachnoid hemorrhage undergoing intracranial aneurysm surgery. J Neurosurg Anesthesiol. 2010;22(3):230–9.CrossRefPubMed
61.
Harasawa R, Hayashi Y, Iwasaki M, et al. Bolus administration of landiolol, a short-acting, selective β1-blocker, to treat tachycardia during anesthesia: a dose-dependent study. J Cardiothorac Vasc Anesth. 2006;20(6):793–5.CrossRefPubMed
62.
Fox EJ, Sklar GS, Hill CH, et al. Complications related to the pressor response to endotracheal intubation. Anesthesiology. 1977;47(6):524–5.CrossRefPubMed
63.
Forbes AM, Dally FG. Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. Br J Anaesth. 1970;42(7):618–24.CrossRefPubMed
64.
Tanabe T, Fukusaki M, Fujinaga A, et al. Landiolol, a new ultra-short-acting β1-blocker, reduces anaesthetic requirement during sevoflurane/N2O/fentanyl anaesthesia in surgical patients. Eur J Anaesthesiol. 2009;26(1):39–42.CrossRefPubMed
65.
Kitamura A, Sakamoto A, Inoue T, et al. Efficacy of an ultrashort-acting β-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol. 1997;51(6):467–71.CrossRefPubMed
66.
Yamazaki A, Kinoshita H, Shimogai M, et al. Landiolol attenuates tachycardia in response to endotracheal intubation without affecting blood pressure. Can J Anaesth. 2005;52(3):254–7.CrossRefPubMed
67.
Ishikawa K, Shirakawa K, Nagao M, et al. Comparison of remifentanil and landiolol on hemodynamic and plasma catecholamine responses to tracheal intubation. Dokkyo J Med Sci. 2012;39(1):1–8.
68.
Kadoi Y, Horiuchi T, Uchida S, et al. Adequacy of control of preoperative hypertension can affect landiolol-induced hemodynamic changes in elderly patients during emergence from anesthesia. J Anesth. 2011;25(2):271–7.CrossRefPubMed
69.
Kawaguchi M, Kawaraguchi Y, Yamamoto Y, et al. Effects of landiolol on systemic and cerebral hemodynamics and recovery from anesthesia in patients undergoing craniotomy. J Anesth. 2010;24(4):503–10.CrossRefPubMed
70.
Miyazaki M, Kadoi Y, Saito S. Effects of landiolol, a short-acting β1-blocker, on hemodynamic variables during emergence from anesthesia and tracheal extubation in elderly patients with and without hypertension. J Anesth. 2009;23(4):483–8.CrossRefPubMed
71.
Shirasaka T, Iwasaki T, Hosokawa N, et al. Effects of landiolol on the cardiovascular response during tracheal extubation. J Anesth. 2008;22(3):322–5.CrossRefPubMed
72.
Suehiro K, Okutani R. Landiolol attenuates cardiovascular response at induction of general anesthesia for cesarean delivery. J Anesth. 2012;26(2):200–5.CrossRefPubMed
73.
Oda Y, Nishikawa K, Hase I, et al. The short-acting β1-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. Anesth Analg. 2005;100(3):733–7.CrossRefPubMed
74.
Sugiura S, Seki S, Hidaka K, et al. The hemodynamic effects of landiolol, an ultra-short-acting β1-selective blocker, on endotracheal intubation in patients with and without hypertension. Anesth Analg. 2007;104(1):124–9.CrossRefPubMed
75.
Kawaguchi M, Takamatsu I, Masui K, et al. Effect of landiolol on bispectral index and spectral entropy responses to tracheal intubation during propofol anaesthesia. Br J Anaesth. 2008;101(2):273–8.CrossRefPubMed
76.
Goyagi T, Tanaka M, Nishikawa T. Landiolol attenuates the cardiovascular response to tracheal intubation. J Anesth. 2005;19(4):282–6.CrossRefPubMed
77.
Hirata N, Miyashita R, Watanabe A, et al. Low-dose continuous infusion of landiolol can reduce adrenergic response during tracheal intubation in elderly patients with cardiovascular disease. J Anesth. 2010;24(5):786–8.CrossRefPubMed
78.
Hirota K, Baba S, Fukushi S, et al. Efficacy of landiolol in attenuating hemodynamic responses to local epinephrine infiltration in patients undergoing vaginal total hysterectomy. J Anesth. 2005;19(1):17–20.CrossRefPubMed
79.
Horiuchi T, Uchida S, Kadoi Y, et al. Landiolol infusion attenuates increase in heart rate, but does not prevent increase in blood pressure in response to emergence from anesthesia and tracheal extubation (in Japanese). Jpn J Anesthesiol. 2010;59(9):1178–84.
80.
Onaka M, Yamamoto H. Effects of continuous infusion of landiolol on the hemodynamic response to tracheal intubation (in Japanese). Jpn J Anesthesiol. 2006;55(2):174–8.
81.
Kawano T, Eguchi S, Iseki A, et al. Effects of landiolol on cardiovascular responses, bispectral index and body movement during endotracheal intubation (in Japanese). Jpn J Anesthesiol. 2005;54(6):610–4.
82.
Tachikawa M, Shimazaki M, Arai T, et al. Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting [in Japanese]. Jpn J Anesthesiol. 2012;61(6):566–73.
83.
Nishiyama Y. The effect of landiolol on bispectral index scores in patients undergoing lower abdominal surgery (in Japanese). Jpn J Anesthesiol. 2012;61(2):217–20.
84.
Goto K, Shingu C, Miyamoto S, et al. The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. J Clin Anesth. 2007;19(7):523–9.CrossRefPubMed
85.
Miyazaki M, Kadoi Y, Takashi S, et al. Comparative effects of propofol, landiolol, and nicardipine on hemodynamic and bispectral index responses to endotracheal intubation: a prospective, randomized, double-blinded study. J Clin Anesth. 2008;20(4):257–62.CrossRefPubMed
86.
Kaneko M, Yamaguchi S, Hamaguchi S, et al. Effects of landiolol on QT interval and QT dispersion during induction of anesthesia using computerized measurement. J Clin Anesth. 2009;21(8):555–61.CrossRefPubMed
87.
Inoue S, Tanaka Y, Kawaguchi M, et al. The efficacy of landiolol for suppressing the hyperdynamic response following laryngoscopy and tracheal intubation: a systematic review. Anaesth Intensive Care. 2009;37(6):893–902.PubMed
88.
Nonaka A, Suzuki S, Abe F. The effects of continuous infusion of landiolol on heart rate changes after neostigmine-atropine administration during recovery from general anesthesia (in Japanese). Jpn J Anesthesiol. 2006;55(12):1459–62.
89.
Wajima Z, Tsuchida H, Shiga T, et al. Intravenous landiolol, a novel β1-adrenergic blocker, reduces the minimum alveolar concentration of sevoflurane in women. J Clin Anesth. 2011;23(4):292–6.CrossRefPubMed
90.
Takizawa D, Saito S, Sato E, et al. Influence of landiolol on the dose requirement of propofol for induction of anesthesia. Fundam Clin Pharmacol. 2005;19(5):597–9.CrossRefPubMed
91.
Goto K, Hagiwara S, Hidaka S, et al. The effect of landiolol on cerebral blood flow in patients undergoing off-pump coronary artery bypass surgery. J Anesth. 2010;24(1):11–6.CrossRefPubMed
92.
Matsura M, Fujiwara Y, Ito H, et al. Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol. J ECT. 2010;26(1):37–40.CrossRefPubMed
93.
Nomoto K, Suzuki T, Serada K, et al. Effects of landiolol on hemodynamic response and seizure duration during electroconvulsive therapy. J Anesth. 2006;20(3):183–7.CrossRefPubMed
94.
Sakamoto A, Ogawa R, Suzuki H, et al. Landiolol attenuates acute hemodynamic responses but does not reduce seizure duration during maintenance electroconvulsive therapy. Psychiatry Clin Neurosci. 2004;58(6):630–5.CrossRefPubMed
95.
Saito S, Nishihara F, Akihiro T, et al. Landiolol and esmolol prevent tachycardia without altering cerebral blood flow. Can J Anaesth. 2005;52(10):1027–34.CrossRefPubMed
96.
Ide M, Kadoi Y, Saito S, et al. Effects of landiolol on left ventricular function during electroconvulsive therapy: a transthoracic echocardiographic study. J Anesth. 2010;24(2):272–6.CrossRefPubMed
97.
Wajima Z, Shiga T, Imanaga K, et al. Prophylactic continuous administration of landiolol, a novel β1 blocker, blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity. Int J Psych Clin Pract. 2010;14(2):132–6.CrossRef
98.
Park H, Otani H, Noda T, et al. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. Int J Cardiol. 2012; doi:10.​1016/​j.​ijcard.​2012.​04.​096.
99.
Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76(2):439–45.CrossRefPubMed
100.
Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study. J Cardiol. 2012;60(4):252–6.CrossRefPubMed
101.
Higuchi H. Feasibility of continuous intravenous administration of landiolol for acute myocardial infarction: first clinical experience and its safe directions for use (abstract no. E953). J Am Coll Cardiol. 2010;55(10 Suppl):A102.
102.
Morita H, Kono T, Suzuki S, et al. Intravenous administration of subdepressor dose of short-acting beta-blocker landiolol before percutaneous coronary intervention may reduce the incidence of myocardial infarction in stable angina (abstract no. 1041-157). J Am Coll Cardiol. 2009:A342.
103.
Mitchell LB. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol. 2011;27(1):91–7.CrossRefPubMed
104.
Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30(22):2769–812.CrossRefPubMed
105.
Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123(10):e269–367.CrossRefPubMed
106.
Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias - executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493–531.CrossRefPubMed
107.
Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012;72(1):109–32.CrossRefPubMed
Metadata
Title
Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias
Author
Greg L. Plosker
Publication date
01-06-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 9/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0077-4

Other articles of this Issue 9/2013

Drugs 9/2013 Go to the issue

R&D Insight Report

Metreleptin: First Global Approval

Leading Article

New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy

R&D Insight Report

Canagliflozin: First Global Approval

Review Article

Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

Adis Drug Evaluation

Loteprednol Etabonate Ophthalmic Gel 0.5 %: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery

Therapy in Practice

HIV-Associated Neurocognitive Disorders: Perspective on Management Strategies